A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, double-blind, parallel-group, single dose study to evaluate
the safety and efficacy of 2 dose levels of REGN475 compared with placebo in patients with
sciatic pain. Enrollment of approximately 50 patients in each of the 3 treatment arms is
expected at up to 35 US sites, for a total enrollment of approximately 150 patients. Patients
will receive 1 injection under the skin of either active or placebo REGN475, and be followed
over 10 visits for 12 weeks.